# Th17 T cell-inducing vaccines for the prevention of ovarian cancer recurrence

> **NIH NIH P50** · MAYO CLINIC ROCHESTER · 2024 · $202,553

## Abstract

The overall goal of this project is to perform preclinical and phase II clinical testing of a Th17-induced pulsed dendritic cell vaccine to assess its efficacy in preventing relapse of high grade ovarian cancer in first remission after debulking surgery and platinum-based adjuvant or neoadjuvant chemotherapy.

## Key facts

- **NIH application ID:** 11041232
- **Project number:** 5P50CA136393-14
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** Matthew Stephen Block
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $202,553
- **Award type:** 5
- **Project period:** 2009-07-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11041232

## Citation

> US National Institutes of Health, RePORTER application 11041232, Th17 T cell-inducing vaccines for the prevention of ovarian cancer recurrence (5P50CA136393-14). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11041232. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*